



# CALL FOR APPLICATIONS 2023

**FONDAZIONE ROCHE**  
VIA IN LUCINA, 17  
00186 ROMA  
[italy.ricerca@roche.com](mailto:italy.ricerca@roche.com)

## Foreword

Research and innovation should be the driver of development in this country and, in the healthcare field, they represent the key to improve people's quality of life.

For the past 125 years, Roche has made research its core business: we believe that being alongside Italians has always meant striving to find new treatments to make a tangible contribution to improve patient's lives.

The road that leads to this ambitious objective is a long one, requiring a great deal of work, commitment and resources. It is a road that cannot be undertaken alone. This is why we decided to fund research, and not just our own. Indeed, the main strategic objective of Fondazione Roche is to promote independent research, in order to support those people who every day have the courage to follow new paths, overcome failures with tenacity, dedication and creativity and carry forward, often in the silence of a laboratory, something great: the progress of healthcare.

This is why Fondazione Roche every year sponsors a call for applications to support research projects promoted by public or private organisations working in the scientific/healthcare sector and that are inspired by the courage to pursue innovative pathways.

### 1. Purposes of the Call for applications

**Fondazione Roche**, whose registered offices are in via in Lucina 17, Rome, is publishing this annual call for applications, with the title "**Roche per la Ricerca 2023**" (hereinafter "Call for applications"), in order to fund research projects for personalised pharmacological approaches. With this Call for applications, Fondazione Roche intends to sponsor 8 (eight) research projects, to be selected – as described under article 8 below - by **Springer Nature Limited** (hereinafter "Springer Nature"), a world leading research, educational and professional publisher.

### 2. Resources available

2.1 The resources that have been set aside for this Call for applications amount to a total of

**€ 400,000.00** [four hundred thousand].

2.2 Each of the 8 winning projects will be sponsored by Fondazione Roche with a fixed grant of € 50,000.00 (fifty thousand), according to the criteria laid down in section 8.

### **3. Addressees**

3.1 This Call for applications is addressed to public or private Organisations (e.g. Hospital and Hospital-University structures, public and private IRCCS) operating in the health or scientific research sector, provided they are legal entities and provided they have their registered and operational Headquarters in Italy (hereinafter, for brevity, "Organisations"), which meet the requirements set out in this Call for applications, as well as the current Legislation.

For the purpose of the validity of its application, each Organisation, upon its adhesion to this Call for applications, will be called to formally certify continuative possession of requirements envisaged by the Call for applications itself, in addition to its commitment not to reinvest or reuse, in case of winning, the grant obtained to generate profits for any reason.

In the lack of thereof, the evaluator reserves the right to go through the final ranking to identify the participants matching the aforementioned requirements, even after the allocation of the grant itself which, in this case, will consequently be reallocated.

3.2 The lead researcher (PI – Principal Investigator) that submits the project on behalf and for the account of the Organisation must be employed by an Italian University, Research Institute or Hospital but without any specific limitations, meaning that the relationship between the two parties can be of any nature. The PI must hold a professional degree (PhD, MD, PharmD).

3.3 In order to guarantee the absence of any potential conflict of interest in the assessment of the research projects promoted by the Organisations indicated in point 3.1, research projects on Roche's medicinal or diagnostic products, and research projects conducted jointly by Roche and external partners, in which Roche obtains information, data, intellectual rights or other benefits in exchange for funding, are excluded from this Call for applications.

3.4 The payment of the grants by Fondazione Roche does not involve any commercial consideration and shall never be made available in order to induce or encourage the prescription, use or

purchase of Roche products.

3.5 Each organisation that is awarded a research grant, must be the actual beneficiary, i.e. the recipient and direct user of the grant.

3.6 Each Organisation taking part in the Call for applications shall maintain full ownership over any invention or right generated by the research project, without Fondazione Roche or any other Roche Group company being entitled to any interest, right or faculty in the same.

3.7 Organisations and other legal entities to which any directors of Fondazione Roche, Roche S.p.A. or other Roche Group companies and their spouses and family or first- or second-degree relations may belong cannot take part in this Call for applications.

3.8 Subjects and organisations that have taken part in and/or benefitted from contributions in previous editions of “Bando Roche per la Ricerca” may take part in this Call for applications, without any kind of restriction.

3.9 Participation in this Call for applications is free of charge.

#### 4. Type of projects eligible

4.1 A deep understanding of several factors affecting different diseases development and tailored clinical management is the key to find better solutions for patients care. Research projects on the topics which fall within the following **Areas**, are eligible for submission for the Call for applications:

- **ONCOLOGY AREA**

TOPICS:

- Biological heterogeneity of cancer
- Prediction of molecular and/or biological response to cancer treatment (i.e.

- immunotherapy, target therapies, biologic agents)
- Mechanisms of immune checkpoint inhibition and immune escape
- Cancer stem cell maintenance mechanisms
- Study of cell microenvironment processes and the dynamics of immune suppression/stimulation
- Role of the microbiota in cancer development
- Characterisation of neoantigens in solid tumors

- **HAEMATO-ONCOLOGY AREA**

TOPICS:

- Biological heterogeneity of blood malignancies
- Prediction of molecular and/or biological response to blood cancer treatments (ie. immunotherapy, target therapies, biologic agents)
- Study of cell microenvironment processes and the dynamics of immune suppression/stimulation
- Mechanisms of haematopoietic stem cell maintenance
- Characterisation of neoantigens in blood malignancies

- **OPHTHALMOLOGY AREA**

TOPICS:

- Epidemiology, pathophysiology and the role of biomarkers in retinal diseases, especially diabetic retinopathy and age related macular degeneration
- Home and remote monitoring tools in retina diseases
- Research projects on retinal imaging (high resolution imaging; adaptive optics etc) aimed at visualizing the vascular stability in Diabetic Retinopathy and AMD (choriocapillaris maintenance; endothelial cell integrity; pericyte coverage; leukostasis and microinflammation)

- **NEUROSCIENCES AREA**

TOPICS:

- Epidemiology, pathophysiology and the role of biomarkers in neurological, neuroinflammatory diseases, especially Multiple Sclerosis, and Neuromyelitis Optica-Spectrum Disorder
- Epidemiology, Disease Outcomes, Outcome Measures and Biomarkers as prognostic and predictive factors in Spinal Muscular Atrophy and Duchenne Muscular Dystrophy
- Cognitive rehabilitations and/or digital assessment in Multiple Sclerosis

- **HEREDITARY CLOTTING DISEASES AREA**

TOPICS:

- Translational research regarding the development of inhibitors or the identification of other associated risk factors
- Studies on comorbidities, bleeding, pain, joint status, aging and Quality of Life (QoL) in congenital haemorrhagic disorders
- Characterization of molecular mechanisms underlying the micro-bleeding of joints in congenital haemorrhagic disorders
- Studies regarding in vitro detection of possible biochemical mechanisms of interaction between molecules involved in management of congenital clotting diseases
- Research projects on the optimization of advanced genetic tests for the non-invasive prenatal diagnosis of congenital bleeding disorders (such as haemophilia)

## **5. Documentation required for submission**

5.1 Any Organisation wishing to take part in this Call for applications must submit its application through the website [www.rocheperlaricerca.it](http://www.rocheperlaricerca.it). Research projects may not be submitted using procedures other than those described in this document.

5.2 Any Organisation applying for a grant must enter the following information through the website [www.rocheperlaricerca.it](http://www.rocheperlaricerca.it):

- general information on the Organisation;
- general information on the Principal Investigator (PI), including the H-index and the Curriculum Vitae;
- detailed description of the project and the purposes for which sponsorship is being sought, using the standard format that can be downloaded from [www.rocheperlaricerca.it](http://www.rocheperlaricerca.it).

5.3 The project submitted for consideration must be accompanied by a timeline (GANTT charting) of a maximum of 12 months (extension may be granted upon request and after proper justification) using the standard format that can be downloaded from [www.rocheperlaricerca.it](http://www.rocheperlaricerca.it).

5.4 Each project can be submitted for just one area. If the same project is submitted to two or more different areas, it will be excluded from the Call for applications.

5.6 Any fraudulent documents or untruthful declarations shall constitute the grounds for disqualification from the Call for applications, even once the selection phase is completed, potential disqualification from future payments and the application of the sanctions envisaged by applicable law.

## **6. Terms and procedures for application submission**

6.1 In order to take part in this Call for applications, the Organisations applying for the grant must submit their application, complete with all the necessary information, between **March 2<sup>nd</sup> 2023 (from 15:00 GMT+1) – Jun 5<sup>th</sup> 2023 (until 17:00 GMT+1)**, using the website [www.rocheperlaricerca.it](http://www.rocheperlaricerca.it).

6.2 Each Organisation may submit, in each area, more than one project without any restriction or numerical limit in relation to the areas listed under article 4, but each principal investigator (PI) can only submit one application.

6.3 Participants assume responsibility for the proprietorship of the research projects, their content

and all other aspects imposed by applicable regulations. Consequently, Fondazione Roche and Springer Nature shall not be held responsible for breaches of rights by third parties.

6.4 Applications received after the deadline and/or submitted using procedures other than that described and/or not accompanied by all the necessary documentation shall not be taken into consideration. Fondazione Roche shall not accept responsibility for delayed receipt or failed delivery of applications due to electronic faults or other cases that cannot be attributed to it.

6.5 The projects and all attachments must be in the English language.

6.7 At the Call for applications deadline, the principal investigator (PI) must be under 40 years of age, without any limits with regard to the position of the PI or his/her relationship with the Organisation.

6.8 Any additional requests for clarification must be forwarded by email to the address: [italy.ricerca@roche.com](mailto:italy.ricerca@roche.com).

## **7. Eligibility criteria**

7.1 Applications shall be considered unacceptable if they:

- are submitted by Organisations that do not meet the requirements set forth under article 3;
- do not meet the criteria established for each type of project set forth under article 4;
- do not comply with the terms and/or requirements and/or submission procedures described in article 6.

## **8. Project assessment and selection process**

8.1 The submitted projects will be assessed and selected by an independent panel of experts under the administration of Springer Nature Limited, a company incorporated in England and Wales (company number 00785998), whose registered office is at The Campus, 4 Crinan Street, London, United Kingdom, N1 9XW. This appointment guarantees the impartiality, detachment and



transparency of the selection process. Roche shall not participate in any way in the choice of the reviewers, application review, or the selection of the grant-winning projects.

8.2 The project assessment and selection process shall involve the following phases:

**Phase 1: Identification of the panel of experts**

Springer Nature shall convene and appoint an international Panel of experts suitably qualified to evaluate the applications. The Panel shall operate independently of Fondazione Roche and Springer Nature.

**Phase 2: Triage**

Springer Nature shall exclude all projects that do not meet the eligibility criteria, and shall triage all applications based on key evaluation criteria in order to create a longlist.

**Phase 3: Review of longlist**

Each longlisted application shall be evaluated by at least two different panel members using a consistent set of evaluation criteria and a consistent scoring methodology.

The score assigned by each panelist to the individual project will be evaluated on the basis of the following criteria:

**Innovation**

Research funded under the programme must contribute to knowledge of the field. Research proposals should explain the originality of the proposed research. This may include novel insights into the field of study or the development of novel techniques.

**Potential impact**

Research proposals should set out the importance of the contribution they will make. For example, the research may directly answer key questions, develop techniques to further probe crucial aspects

of the field or address unmet challenges or opportunities. The ultimate aim of the scheme is to benefit society and patients through improved knowledge, tools and techniques to understand and address human health.

### **Scientific quality**

Research Proposals must set out well-designed, robust studies using the most appropriate methodologies, equipment, data and analytical techniques to reach the stated objectives.

### **Quality of the applicant/team**

The applicant (and other team members) must have the necessary skills and experience to carry out the research, both in terms of the science and the leadership of a research grant. This will be judged on the track record of the applicant(s) and the appropriateness of the host universities and institutes.

### **Value for money**

The project budget must be clearly explained and will be judged on the appropriateness to deliver the proposed programme of research. This is not about costing the project as cheaply as possible, it is about showing why the requested resources are necessary and reassuring the panel that everything is in place to conduct the research and deliver on the objectives. The panel will also consider how the project will be managed to ensure the resources are deployed effectively.

### **Phase 4: Meeting of Panel**

Based on the combined scores of the panelists for each longlisted application, a shortlist of applications shall be created. Each of the panel members shall review all of the shortlisted applications, and shall meet to make final decisions of which applications to fund. Neither Roche nor Springer Nature shall influence the decisions of the Panel.

On the basis of the final ranking elaborated by the Panel, the 8 winning projects (**2+2 related to the Oncology and Neurosciences Areas, 1+1+1 related to Haemato-Oncology, Ophthalmology, Hereditary Clotting Diseases Areas and 1 related to the application with the highest score**

**within the final ranking regardless of the Area)** will be selected.

In the event that it is not possible to assign the contribution for one or more areas, the contribution will be assigned to the first/first non-funded project(s) in the final ranking, regardless of the area.

8.3 Springer Nature and the reviewers nevertheless have absolute discretion with regard to assessment of the satisfaction and/or relevance of the eligibility requirements and aforesaid criteria.

8.4 The opinion of Springer Nature and the Panel of experts is unchallengeable and, consequently, appeals, complaints, re-examination requests or any other form of objection shall not be permitted.

## **9. Announcement of the winning projects and award ceremony**

9.1 Further to grant assessment, Springer Nature will inform Fondazione Roche of the grant-winning Organisations **by October 6<sup>th</sup> 2023**. This will be followed by the communication to the 8 winning PI and to all the applicants. Applicants will be allowed to access their own personal area on the website [www.rocheperlaricerca.it](http://www.rocheperlaricerca.it) to know the score assigned by Springer Nature and the position in the final ranking. It will not be possible to view any details relating to the evaluation carried out by the Panel. On the website will be published all the details regarding the award ceremony. The 8 winners will receive a dedicated communication from the email account [italy.ricerca@roche.com](mailto:italy.ricerca@roche.com).

9.2 Fondazione Roche shall cover the travel and hospitality costs for one representative of each winning Organisation.

9.3 **Within 1 week** of the receipt of the communication, the winning principal investigators (PI) must provide to Fondazione Roche the following information:

- declaration signed by the Legal Representative of the Organisation - or special attorney in accordance with an attached power of attorney document - certifying the undertaking to provide, at the end of the project, documentation confirming that the project for which

sponsorship was sought was actually completed;

- if the Organisation is a private subject, the Articles of Association or, alternatively, the Articles of Organisation, must also be provided.

## **10. Awarding of the grant and payment procedure**

10.1 The grant shall be paid **by the end of October 2023** and the winners shall be notified of the details of payment directly from Fondazione Roche.

## **11. Documentation certifying the start and completion of the research project**

11.1 The project must be started **within 6 months** of the date on which Fondazione Roche paid the grant.

11.2 **Within 6 months** of the time the grant was paid, each grant-winning Organisation is under obligation to send a declaration confirming that the research project has been started to the email address: [italy.ricerca@roche.com](mailto:italy.ricerca@roche.com), in order to allow Fondazione Roche to make the appropriate checks.

11.3 **Within 36 months** of the project start date, each grant-winning Organisation is under obligation to send to the email address: [italy.ricerca@roche.com](mailto:italy.ricerca@roche.com) the documentation confirming that the grant received from Fondazione Roche was actually used to support the research project.

## **12. Publication of the Call for applications**

12.1 This Call for applications and the corresponding documentation are published on the dedicated website: [www.rocheperlaricerca.it](http://www.rocheperlaricerca.it).